aclarubicin

P3, N=40, Active, not recruiting, Fujian Medical University Union Hospital

P1/2, N=37, Not yet recruiting, Shanghai Jiao Tong University School of Medicine

P2, N=36, Not yet recruiting, Shanghai Jiao Tong University School of Medicine

P2, N=120, Recruiting, Chinese PLA General Hospital

P2, N=200, Recruiting, Chinese PLA General Hospital | Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Jan 2026 --> Jan 2029

P1/2, N=112, Not yet recruiting, Shanghai Jiao Tong University School of Medicine

P2, N=160, Active, not recruiting, Chinese PLA General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2026 --> Sep 2025

Initial therapy with a decitabine-CAG (aclacinomycin, cytarabine, G-CSF)-venetoclax regimen failed to induce remission. Morphological complete remission was achieved after switching to a DAE (daunorubicin, cytarabine, etoposide) regimen...This case highlights the diagnostic and therapeutic complexities associated with the co-occurrence of AEL and HLH. Early identification of HLH as a potential complication in AEL is crucial, though outcomes remain dismal, emphasizing an urgent need for novel therapeutic strategies.

This study evaluated the clinical efficacy of venetoclax and azacitidine (VEN+AZA) versus CAG (cytarabine, aclarubicin, and granulocyte colony-stimulating factor) for newly diagnosed adult acute myeloid leukemia (AML) unfit patients. 31.7 % (P = 0.20). Patients with age ≥ 60 y (EFS, P = 0.032), ECOG≥ 2 (EFS, P = 0.047), secondary AML (OS, P = 0.015; EFS, P = 0.039), ELN intermediate-adverse karyotype (OS, P = 0.034; EFS, P = 0.044), RUNX1 mutation (OS, P = 0.003; EFS, P = 0.003) and IDH1/2 mutation (EFS, P = 0.039) showed a preference for VEN+AZA regarding OS, and patients with SRSF2 mutation favored CAG in OS (P = 0.031).

P2, N=200, Completed, Chinese PLA General Hospital | Recruiting --> Completed

In patients with R/R AML, the CACAG-VEN regimen resulted in significant clinical benefits, with a high CRc rate and encouraging survival, as well as being well tolerated. https://www.chictr.org.cn/, identifier, ChiCTR2200065634.

Infiltrative mediastinal/retroperitoneal MS may present with esophageal obstruction and mimic lymphoma or carcinoma. High-index suspicion, targeted biopsy with high-power morphology, and a focused immunohistochemical panel are critical for timely diagnosis and treatment initiation.